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Introduction
Penile erection depends on a complex interaction
between neurological stimuli and smooth muscle fibre
relaxation within the penis. These neurovascular events
are influenced by hormonal and psychological status. 
Penile erection is initiated when neurological stimula-
tion results in a decrease in orthosympatic tonus, respon-
sible for penile flaccidity. This stimulation leads to an
activation of both the parasympathic system and a nona-
drenergic noncholinergic system. The main mechanism
controlling for corporal smooth muscle fibre relaxation
is the nitric oxide pathway, which, via an increase in
cyclic guanosine monophosphate (cGMP) and a drop in
intracellular calcium within smooth muscle fibres, caus-
es the opening of the small penile arteries and lacunar
spaces of the cavernous body. It is note worthy that
smooth muscle cells are the true agents controlling
penile erection. Nitric oxide (NO), produced by nitric
oxide synthase (NOS) within an oxygenated medium, is
released by afferent nerve terminals subserving the cav-
ernous body, as well as by endothelial cells, under the
action of erectogenic stimuli. NO has been shown to play
a significant role in regulating both vascular tone and
vascular reactivity. As a result, a several-fold increase in
penile arterial blood flow occurs. Certain studies have
revealed androgens to play a significant role in improv-
ing NO-synthase activity.
This increase in penile blood flow alone does not
 produce a rigid penile erection but allows for the devel-
opment of penile tumescence. To achieve erection, an
additional veno-occlusive phenomenon is required,
which largely suppresses venous outlow from the
 cavernous bodies. 
Under normal circumstances, compression of
 albugineal venules allows the intracavernous compart-
ment to function as a closed system, a real active sponge. 
The penis becomes very rigid and at this stage,  arteri-
al blood flow significantly decreases until reaching
 equilibrium with the minor physiological blood escape
from the cavernous bodies, which is instrumental in
maintaining the erection. The bulbocavernous reflex is
triggered causing ischiocavernous muscles, surrounding
the “dead space” on the posterior part of the cavernous
bodies, to forcefully contract, resulting in further intra-
cavernous pressure rise. 
Ejaculation, along with its orthosympathic activation,
inverts the process and causes detumescence. During the
return to the flaccid state, cGMP is hydrolysed to guano-
sine monophosphate by phosphodiesterase type 5
(PDE5) within smooth muscle fibres, with a return of
arterial luminae and cavernous body tonus to resting val-
ues. 
Erectile dysfunction as a barometer of vascular
health
Erectile dysfunction (ED) is defined as the persistent
inability to achieve and/or maintain an appropriate erec-
tion, enabling satisfactory and successful intercourse.
The prevalence of erectile dysfunction is high and,
according to MMAS study (1), a major American trial in
this field of research, ED affects 22% of men aged 22 to
29 years, increasing to 49% among those aged 70 to
79 years. These American findings have been confirmed
by more recent European study results. ED is highly age-
dependent but also relates to a variety of cardiovascular,
urological, neurological, and hormonal risk factors,
including penile traumatisms. 
Lipid anomalies, hypertension, diabetes, smoking,
obesity, and lack of exercise are shared risk factors for
both cardiovascular diseases and ED. In addition, a vari-
ety of medical and social conditions have been shown to
increase the risk of developing ED (2, 3) (Table I).
ED is an isolated or combined failure of different
 psychological, hormonal, neurological, vascular and
 cavernous body systems that are implicated in causing
penile erection. 
ED may additionally be caused by various drugs, such
as centrally acting antihypertensive drugs, anti -
depressants, antihistaminics, and antiandrogens.
Moreover, its occurrence may be facilitated by misuse of
legal or illegal substances, such as tobacco, alcohol,
cocaine, heroine, and methadone.
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According to both clinical experience and epidemio-
logical studies, the risk of developing ED is significantly
increased in patients presenting concomitant cardiovas-
cular risk factors (MALES study – Table II). 
Cardiovascular disease is thus recognised to be the
most frequent cause of ED. 
In addition, the metabolic syndrome which associates
abdominal obesity, insulin resistance, hypertension, and
dyslipidemia, is frequently associated with ED. Current
evidence strongly suggests that this condition of multi-
factorial origin is often accompanied by hypogonadism.
Currently, due to the accumulation of risk factors, meta-
bolic syndrome is considered to be an important predic-
tor of ED. 
In the case of diabetes, atherogenic dyslipidemia (low
HDL cholesterol, elevated triglycerides, and increased
small and dense LDL particles), hypertension, obesity,
smoking, and ED, common shared features of these con-
ditions are vascular corporal endothelial damage and
decreased penile blood supply. More precisely, the
endothelial lesion resulting from cardiovascular risk fac-
tors is associated with inflammatory reactions, vasocon-
striction, thrombosis, and atherosclerosis (Fig. 1).
Endothelial injury is also caused by increased oxida-
tive stress with excessive free radical formation, altered
NO production, or decreased expression of VEGF (4).
Thus, within the endothelial penile system, the loss of
functional endothelial integrity and drop in NO bio -
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activity induce alterations in smooth muscle reactivity
and relaxation, which eventually leads to ED. 
Moreover, by altering corporal fibroelastic structures,
hypercholesterolemia and diabetes decrease tissue com-
pliance and result in veno-occlusive dysfunction. The
penis thus becomes sclerotic, diminishing in size and
elasticity. 
ED might be a clinical predictor of cardiovascular dis-
eases that have not yet become apparent (5). In fact,
while similar mechanisms of tissue ischemia appear to
underlie both ED and cardiovascular diseases, the symp-
toms related to vascular obstruction occur at an earlier
time in organs presenting a fine vascular structure such
as the penis, as compared to those receiving blood  sup-
ply from big arteries (myocardial infarct) (6) (Fig. 2).
Percentages of luminal obstruction are presented at
the bottom. 
An angiographic obstruction exceeding 50% of the
vessels’ lumen is required for symptoms to occur. The
blue part of the figure represents the plaque mass in a
patient with isolated ED, whereas the yellow part of the
figure illustrates a subsequent stage of atherosclerotic
disease, with a more significant plaque mass in a patient
with clinically manifest coronary artery disease
AMI : acute myocardial infarction ; CAD : coronary
artery disease ; CVD : cerebrovascular disease ; ED :
erectile dysfunction ; PAD : peripheral arterial disease ;
TIA : transient ischemic attack (Montorsi 2003).
Several studies have shown that patients with ED
present a significantly increased long-term risk for
myocardial infarction and cerebrovascular accidents (7,
8). If routine anamnesis would include a questions such
as “do you still have good-quality erections”, the
patients’ answers would enable us to direct complemen-
tary explorations towards coronary and carotid arteries,
thereby facilitating earlier detection of common and
morbid cardiovascular diseases. 
According to an exhaustive literature review covering
papers published from 2002 to 2008, there was substan-
tial clinical evidence that ED was independently related
to subsequent cardiovascular events (mean time interval :
3 years, ESSM 2009), and that 60% of men admitted to
hospital for myocardial infarction presented ED of vari-
able intensity (9). This study, as well as other studies
support the concept that ED constituted a unique oppor-
tunity for detecting at an early stage a clinically non-
apparent cardiovascular disease. According to this con-
cept, failure of the NO pathway would be the common
denominator in the pathophysiology underlying both
ischemic heart disease and ED (10). 
Treating erectile dysfunction with astonishing effica-
cy... is the clinician aware of all of the therapeutic
benefits ?
Since the launch of sildenafil (Viagra) in 1998, inhibitors
of phosphodiesterase type 5 (PDE5i) have been available
Table I
Clinical and social conditions shown to increase risk of

















Prevalence of ED in the presence of cardiovascular risk
 factors in the MALES study
Risk factor (RF)    RF prevalence ED prevalence





Diabetes and one RF 4% 42%
Diabetes and hypertension 3% 42%
Diabetes and angina 2% 46%
Diabetes and hypercholesterolemia 2% 45%
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Fig. 1
Erectile dysfunction at the centre of vascular events
Fig. 2
Arteriosclerotic degradation of different-size arteries : relevance of artery calibre
on the market. Two other products have been extensive-
ly used since 2003, notably vardenafil (Levitra®) and
tadalafil. These drugs are considered first-line therapy
for the majority of ED patients, as they are efficacious
(over 65% in an unselected patient population) and
devoid of significant adverse events (hot flashes,
headaches, dyspepsia, and rhinitis). Although these mol-
ecules belong to the same pharmacological class, they
differ in terms of selectivity, adverse events, and pharma-
cokinetic properties (11). These drugs should not be
administered in association with nitrate therapy and
other NO donors, which are contra-indications to their
use. Furthermore, cytochrome P450-mediated drug inter-
actions may occur, and dose adjustments are likely to be
required in cases of severe renal or hepatic impairment.
For men with pre-existing cardiovascular disease, the
Princeton consensus recommends investigating exercise
tolerance (capability to easily walk up two floors). A car-
diologist consultation is recommended in the case of
sedentary patients with more than three cardiovascular
risk factors and for men with pre-existing coronary dis-
ease, especially if treated using nitrite medications (12). 
Overall, PDE5i amplify the effects of endogenous NO
by blocking cGMP (second messenger for smooth
 muscle relaxation) inactivation, thereby increasing its
concentration, which facilitates massive smooth muscle
relaxation in the penis and better erections.
In clinical practice, goal directed first-line therapy is
based on a “test prescription” of one of the PDE5i.
Patients are then classified into two groups, as “respon-
sive” or “resistant” to PDE5i.
Responsive patients (more than 65% of ED patients )
do not require any additional investigation (13, 14), with
the exception of young patients with no cardiovascular
risk factors. A medical evaluation is conducted, and
reversible risk factors must be corrected and treated. 
In fact, in certain ED cases, the sole correction of an
existing dyslipidemia using atorvastatine has been shown
to improve erectile function (15). The therapeutic man-
agement of arterial hypertension in a patient with ED
appears to be more difficult, as most antihypertensive
medications have a deleterious effect on erectile func-
tion, potentially leading to ED aggravation during thera-
py, which diminishes treatment compliance.
Nevertheless, using losartan in patients suffering from
both arterial hypertension and ED has resulted in erectile
function improvements, with ED levels decreasing from
75.3% to 11.8% within a 12-week time period (16). 
There are only few data regarding the beneficial
effects on ED produced by normalising blood glucose
levels in patients with diabetes. Lifestyle modifications,
such as smoking cessation and weight loss, have only lit-
tle effect on erectile function, whereas correcting a
sedentary lifestyle by enhancing physical activity
appears to be a more promising approach (17). 
156 R. Andrianne and J.-J. Legros
These findings, along with those of other authors,
raise the question as to whether a combination of long-
term medication along with a reduction of risk factors
may allow ED to be successfully treated in patients who
are responsive to PDE5i. The encouraging results
achieved with this approach in some patients suffering
from ED may be accounted for by a revalidation of the
vascular endothelium (18, 19). 
Yet, the overall cardiovascular benefits that ED
patients at risk of developing cardiovascular events may
gain from long-term PDE5i therapy must still be deter-
mined. The results of the first phase 3 and 4 trials with
these molecules are encouraging, as they seem to suggest
a protective effect of PDE5i therapy. However, such a
protective effect still needs to be confirmed in men.
According to Radovits (20), cardioprotection may be
obtained in diabetic patients who present both endothe-
lial and cardiac dysfunctions along with decreased NO
production via increased intracellular cGMP levels.
Based on studies conducted on rats rendered diabetic,
Radovits showed that vardenafil improved cardio -
vascular dysfunction induced by an up-regulation of
NO-cGMP pathways in the vascular wall and myo -
cardium. 
Depending on the clinical condition, first-line therapy
is completed by uro-sexological recommendations,
 cardiovascular prevention measures, and lifestyle
 modifications within a pluridisciplinary medical team. 
Patients, who are resistant to PDE5i, should be
referred to specialists and receive second-line or third-
line therapies, after having undergone additional
 complementary investigations. When confronted with a
heavier therapeutic approach, some patients may resign
themselves to dropping therapy, which is mostly
approved upon by the clinician, provided that a causal
systemic pathology has been excluded or correctly
 treated. 
Second-line therapy consists in intracavernous injec-
tion of vaso-active drugs, such as prostaglandin E1
(Caverject°) or papaverine. For this procedure, a muscle-
relaxing substance aimed at inducing erection is injected
in one of the cavernous bodies so as to attain erection.
The most common side effects of this procedure include
penile pain, prolonged or priapic erections, as well as
local fibrosis. This local therapy may be indicated in
patients who are taking nitrates. 
Another therapeutic option is the use of a vacuum
constriction device, also referred to as erection pump,
which allows the patient to attain an erection via vacuum
suctioning of blood that is trapped in the penis with an
elastic constriction device placed at the penis base. The
side effects of this therapeutic modality include pain,
coldness, trapped ejaculate, and petechiae. This type of
therapy is limited to older and motivated patients, who
are in stable relationships (21). 
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Venous surgery has been abandoned, whereas arterial
revascularisation surgery is rarely used, mainly in young
patients with ED occurring after injuries. 
The use of a penile prosthesis has proven efficacious
in motivated and informed patients, following failure or
refusal of all other treatment options (22). These devices
are implanted directly within the body and function as
substitutes to the erectile apparatus. They are considered
third-line therapy. 
And testosterone ...
For a good-quality erection, oxygen is chiefly required,
as testosterone levels are usually sufficient. Given that
the prevalence of both testosterone deficits and ED
increases with age, it is tempting to assume that hormon-
al aging might account for the occurrence of ED in men,
as testosterone is involved in both sexual desire and erec-
tions (23). However, only few studies have found signif-
icant correlations between testosterone levels and sexual
parameters in older men. Hypogonadism is observed in
only 7.8% of patients with ED, in particular in those
older than 50 years (14.7%).
In observational studies involving hypogonadic ED
patients, substitutive treatment with testosterone resulted
in mitigated effects (36% improvement in non-placebo-
controlled studies) (24, 25, 27-29). 
Therefore, testosterone deficiency observed in some
ED patients does not appear to be the authentic or unique
cause of ED. Severe anomalies of penile arteries are
found in 42% of patients presenting both ED and
 testosterone deficiency (30), and an even higher patient
percentage is likely to be affected by endothelial
 dysfunction. 
In certain cases, low testosterone levels are the con -
sequence rather than the cause of ED. Interestingly, three
studies (25, 31, 32) revealed that successful non-
 hormonal treatment of ED (intracavernous injections,
iPDE5, or penile prostheses) was associated with
 testosterone level normalisation. 
ED-induced sexual hypoactivity, stress, and masked
depression are likely to account for the hypogonadism
that is associated with a reversible dysfunction of LH
activity, under hypothalamic control (31). 
The lack of ED improvement following testosterone
administration in men presenting both ED and testos-
terone deficiency might be explained by the fact that
androgenic treatment was prescribed too late in the
course of ED, at a time when testosterone deficiency had
already led to irreversible vascular endothelial dysfunc-
tion, partly via the development of insulin resistance and
metabolic syndrome (33).
However, despite the poor therapeutic effects of
testosterone in this population, hypogonadism should
always be sought for in patients with ED, as its
 correction improves spontaneous erections (improved
 cavernous oxygenation), sexual desire (improved part-
nership based on sexual fulfilment), other hypogo-
nadism-related parameters (mood and lack of energy), as
well as the efficacy of PDE5i. Furthermore, correcting
hypogonadism might also improve other cardiovascular
parameters, such as cardiac compensation and abnormal
lipid profiles (22bis, 34-38). 
Should other endocrinological problems be detected
in the course of the investigations, they must be properly
addressed by specific treatments.
Further investigations in view of goal-directed therapy
Complementary examinations are focused on vascular,
endocrinological, neurological, or psychosexual aspects.
A general laboratory analysis is conducted, depending
on anamnesis and physical examination findings.
Assessment of testosterone levels is indicated, particular-
ly when suspecting an altered libido. 
As primary investigation for vascular assessment, a
colour pulsed Doppler ultrasonography of the penis must
be performed. To this end, an intracavernous injection of
10 micrograms prostaglandine E1 is carried out, follow-
ing which cavernous tissue reactivity and appearance, as
well as systolic and diastolic flows during the different
phases of penile erection phenomenon are assessed. 
Dynamic cavernous artery blood-flow studies, along
with cavernous ultrasound velocimetry, are considered
the gold standard to confirm a cavernous venous escape,
suspected on Doppler sonographic findings. 
Hyperselective arteriography of internal iliac arteries
and their branches is indicated in selected cases, with
eventual stent placement for internal iliac arteries during
the procedure.
Conclusions that could be of interest for the
 surgeons...
Among the causes of ED, endothelial dysfunction is the
most common shared physiopathological mechanism.
This results in arterial damage, first involving small-
 calibre blood vessels and erectile tissue prior to affecting
coronary and carotid arteries. As the risk factors for ED
are identical to those for cardiovascular diseases, the ED
symptom should be used as a clinical marker in order to
identify patients at risk for subsequent cardiovascular
events. Moreover, ED should be part of the recommenda-
tions for doctors regarding the prevention of cardio -
vascular diseases in clinical practice. 
The diagnosis of ED is easy, provided that the right
question is being asked. 
Treatment of ED is simple using PDE5i monotherapy,
the potential long-term cardiovascular benefits of which
warrant further investigations. 
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